SCHEMBL3249599

SCHEMBL3249599

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(Sc4cccc(NC(C)=O)c4)cc3c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.41
CLEC4M Q9H2X3 1/20 0.41
KDR P35968 2/20 0.40
ADORA3 P0DMS8 1/20 0.40
JAK3 P52333 11/20 0.40
JAK1 P23458 1/20 0.40
JAK2 O60674 3/20 0.40
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39
TUBB6 Q9BUF5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250183 0.92 MMP13 (0.43) MMP13CLEC4MADORA3KDM4EGABRA1
SCHEMBL3241804 0.87 KDR (0.44) KDRKDM4EALDH1A1
SCHEMBL3253148 0.87 TUBB4A (0.47) CLEC4MJAK3JAK2TUBB4ATUBB
SCHEMBL3256086 0.87 KDR (0.38) MMP13KDRADORA3TUBB4ATUBB
SCHEMBL13928204 0.87 MMP13 (0.51) MMP13CLEC4MADORA3KDM4EGABRA1
SCHEMBL3252021 0.87 JAK3 (0.47) MMP13JAK3JAK1JAK2
SCHEMBL3251329 0.86 CLEC4M (0.43) CLEC4MADORA3JAK3JAK2TUBB4A
SCHEMBL4155636 0.80 KDR (0.41) KDRKDM4EALDH1A1MAPT
SCHEMBL3245415 0.79 CHEK1 (0.39) MMP13ADORA3KDM4EALDH1A1LMNA
SCHEMBL13928207 0.79 GABRA1 (0.43) CLEC4MJAK3JAK2KDM4EGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MMP13 3517/4885CLEC4M 4384/4885KDR 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.